Should Investors Buy Into Companies Developing Zika Virus Treatments?

TL;DR

Investing in Zika vaccine companies like Sanofi and Inovio requires caution due to long development timelines.

Transcript

Kristine Harjes: As investors, are there any names we can look to here to try to capitalize on this? Todd Campbell: Developing vaccines is not easy. It can take a very long time. But there are a couple companies that have come out and said they're doing some early work on a vaccine for it-- Harjes: (laughs) Early being the key word. Campbell: Yeah,... Read More

Key Insights

• 💨 Zika vaccine development is a slow and uncertain process, with commercialization potential years away.
• 🍉 Stock boosts from vaccine hype may not accurately reflect a company's near-term financial success.
• 💄 Investors should consider a company's broader portfolio and potential beyond Zika solutions when making investment decisions.
• 🦟 Intrexon's approach to genetically engineering mosquitoes for Zika prevention presents potential but requires cautious evaluation.
• 👨‍🔬 Sanofi and Inovio Pharmaceuticals are among the companies conducting early-stage research on Zika vaccines.
• 🍉 Long-term considerations should outweigh short-term hype when investing in Zika-related companies.
• ❓ Investors should approach Zika investments with caution and consider the overall market potential of a company beyond its Zika initiatives.

Questions & Answers

Q: What are some companies working on Zika vaccines?

Sanofi and Inovio Pharmaceuticals are conducting early research on Zika vaccines. Sanofi leverages past vaccine experience, while Inovio uses DNA technology in preclinical studies.

Q: Why should investors approach Zika vaccine investments cautiously?

Vaccine development is a time-consuming process, and stock boosts from hype may not reflect near-term commercialization. Investing based solely on Zika potential is risky.

Q: How does Intrexon contribute to Zika prevention efforts?

Intrexon explores engineering mosquito DNA to prevent Zika transmission. However, the commercial viability of this solution remains uncertain, advising investors to consider broader company aspects.

Q: What advice is given regarding investing in Zika-related companies?

Investors should not overly focus on Zika investments and avoid being swayed by hype. Companies like Sanofi offer diversified portfolios beyond Zika that may provide more stable investment opportunities.

Summary & Key Takeaways

• Developing Zika vaccines is a lengthy process, with companies like Sanofi and Inovio Pharmaceuticals in early stages of research.

• Investors should be wary of stock boosts based on vaccine development hype, as commercialization could take years to materialize.

• Companies like Intrexon aim to engineer mosquito DNA to prevent Zika transmission, but investment decisions should consider broader company potential beyond Zika solutions.